Aridis Pharmaceuticals to Present at BIO CEO & Investor Conference 2016
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the...
Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin® for Treating Hospital-Acquired and Ventilator-Associated Pneumonia
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today positive...
Aridis Pharmaceuticals to Present at Biotech Showcase(TM) 2016
Aridis Pharmaceuticals Receives Multiple NIH Grants
-- Proceeds to Fund Development of Several Novel Anti-infective Programs --
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that it has secured several grants...
Aridis Pharmaceuticals Receives FDA Fast Track Designation for AR-301 for Acute Pneumonia caused by Staphylococcus aureus